Whey Protein Support to Metabolic and Performance Adaptations in Response HIIT

January 10, 2020 updated by: Brian Carson, University of Limerick

Whey Protein Support to Metabolic and Performance Adaptations in Response to High Intensity Interval Training in Young Adult Men

High intensity interval training (HIIT) has recently emerged as a time efficient alternative to conventional endurance exercise, conferring similar or superior benefits in terms of metabolic and performance adaptations in both athletic and non-athletic populations. Some of these physiological adaptations include augmented mitochondrial biogenesis and improved substrate metabolism in peripheral tissues such as skeletal muscle. However, nutritional strategies to optimise the adaptations to HIIT have yet to be established. Recent evidence suggests that acute nutritional status can affect the molecular regulation of genes mediating substrate metabolism and mitochondrial biogenesis. Moreover, preliminary evidence suggests that completion of exercise in fasted conditions augments some of these exercise-induced adaptations compared with the fed state. Given the fact that the transient molecular adaptations to acute exercise mediate long-term physiological adaptations, an investigation into the effects of different nutritional interventions on metabolic and performance responses to HIIT is warranted.

The purpose of this study is to determine the effects of fasted vs. fed-state (Whey Protein) HIIT on metabolic and performance adaptations in the acute (single exercise session) and chronic (3 weeks, 9 exercise sessions) phases. The primary hypothesis is that different pre-exercise feeding conditions (e.g. fasted placebo vs. Whey protein fed) will result in divergent physiological adaptations in terms of skeletal muscle metabolism and performance, both in response to a single HIIT session and a chronic HIIT intervention.

Study Overview

Detailed Description

High intensity interval training (HIIT) has recently emerged as a time efficient alternative to conventional endurance exercise, conferring similar or superior benefits in terms of metabolic and performance adaptations in both athletic and non-athletic populations. Some of these physiological adaptations include augmented mitochondrial biogenesis and improved substrate metabolism in peripheral tissues such as skeletal muscle. However, nutritional strategies to optimise the adaptations to HIIT have yet to be established. Recent evidence suggests that acute nutritional status can affect the molecular regulation of genes mediating substrate metabolism and mitochondrial biogenesis. Moreover, preliminary evidence suggests that completion of exercise in fasted conditions augments some of these exercise-induced adaptations compared with the fed state. Given the fact that the transient molecular adaptations to acute exercise mediate long-term physiological adaptations, an investigation into the effects of different nutritional interventions on metabolic and performance responses to HIIT is warranted.

The purpose of this study is to determine the effects of fasted vs. fed-state (Whey Protein) HIIT on metabolic and performance adaptations in the acute (single exercise session) and chronic (3 weeks, 9 exercise sessions) phases. The primary hypothesis is that different pre-exercise feeding conditions (e.g. fasted vs. Whey protein fed) will result in divergent physiological adaptations in terms of skeletal muscle metabolism and performance, both in response to a single HIIT session and a chronic HIIT intervention.

A randomly assigned, parallel group, simple pre-post design has been adopted to answer this question. 3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max <50 ml.kg.min-1), protein sufficient (>0.8 g.kg.d-1), males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following >10h overnight fast: i) Fasted placebo (0.33g.kg-1 body mass artificially flavoured and textured placebo); ii) Fed Whey protein (0.33g.kg-1 body mass intact whey protein 45 minutes prior to exercise); iii) Fed Whey protein hydrolysate (0.33g.kg-1 body mass hydrolysed whey protein 45 minutes prior to exercise). Participants will undergo biological sampling (venous blood and muscle biopsy) and measures of performance pre and post the intervention.

Study Type

Interventional

Enrollment (Actual)

35

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Munster
      • Limerick, Munster, Ireland, V94 T9PX
        • University of Limerick

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Healthy (absence of clinical condition)
  • Recreationally active
  • Aerobically untrained (VO2max <50 ml.kg.min-1)
  • Protein sufficient (>0.8 g.kg.d-1)
  • Males
  • Able to provide informed consent
  • No contraindications to high intensity exercise

Exclusion Criteria:

  • BMI >30 kg.m-2
  • Metabolic disease (mitochondrial, Type 2 Diabetes)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass of artificially flavoured and textured placebo 45 minutes prior to HIIT exercise
3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max <50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following >10h overnight fast: i) Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Fed Whey protein 45 minutes prior to exercise; iii) Fed Whey protein hydrolysate 45 minutes prior to exercise).
Experimental: Whey Protein
Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass intact whey protein 45 minutes prior to HIIT exercise
3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max <50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following >10h overnight fast: i) Placebo: Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Whey protein 45 minutes prior to exercise; iii) Whey protein hydrolysate 45 minutes prior to exercise).
Experimental: Whey Protein Hydrolysate
Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass hydrolysed whey protein 45 minutes prior to HIIT exercise
3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max <50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following >10h overnight fast: i) Placebo: Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Whey protein 45 minutes prior to exercise; iii) Whey protein hydrolysate 45 minutes prior to exercise).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Organelle Biogenesis (Mitochondrial) Acute
Time Frame: Acute - 3 hours post exercise session 1
Acute phase - change in Peroxisome Proliferator Activated Receptor 1 alpha (PGC-1α) messenger ribonucleic acid (mRNA) expression in response to a single HIIT session. Measured using real-time polymerase chain reaction (RT-PCR).
Acute - 3 hours post exercise session 1
Exercise Performance
Time Frame: Chronic - 72 hours post exercise session 9
Mean power output (Watts) during 20 minute cycling performance test. Measured using cycle ergometer and associated software.
Chronic - 72 hours post exercise session 9
Anaerobic Exercise Performance
Time Frame: Chronic - 72 hours post exercise session 9
Anaerobic exercise performance peak power (Watts). Measured using 30 second Wingate test on a Monark 894E cycle ergometer.
Chronic - 72 hours post exercise session 9
Organelle Biogenesis (Mitochondrial) Chronic
Time Frame: Chronic - 48 hours post exercise session 9
Chronic Phase - change in Citrate Synthase Activity measured using commercially available assay kits.
Chronic - 48 hours post exercise session 9

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Organelle Biogenesis (Mitochondrial)
Time Frame: Acute: 3 hours post HIIT session 1.
Pyruvate Dehydrogenase Kinase 4 (PDK4), Peroxisome Proliferator Activated Receptor (PPAR) delta, Sirtuin 1 (SIRT1) mRNA expression. Measured using real-time polymerase chain reaction (RT-PCR).
Acute: 3 hours post HIIT session 1.
Cycling Economy
Time Frame: Chronic - 72 hours post exercise session 9
Cycling economy (W.VO2 L.min-1) during multiple incremental stages (50 W, 100 W, 150 W, 200 W, 250 W) of a submaximal cycling test.
Chronic - 72 hours post exercise session 9

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Brian P Carson, PhD, University of Limerick

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 31, 2018

Primary Completion (Actual)

February 1, 2019

Study Completion (Actual)

February 1, 2019

Study Registration Dates

First Submitted

May 22, 2018

First Submitted That Met QC Criteria

June 15, 2018

First Posted (Actual)

June 27, 2018

Study Record Updates

Last Update Posted (Actual)

January 13, 2020

Last Update Submitted That Met QC Criteria

January 10, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe